Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 302, Issue 9, 2012, Pages

  Christou, Helen ^a,d   Reslan, Ossama M ^b   Mam, Virak ^b   Tanbe, Alain F ^b   Vitali, Sally H ^c   Touma, Marlin ^a,d   Arons, Elena ^a   Alex Mitsialis, S ^d   Kourembanas, Stella ^a,d   Khalil, Raouf A ^b  

^a Division of Newborn Medicine   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Department of Anesthesia ^*  (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Nitric oxide; Pulmonary artery; Pulmonary circulation; Vascular smooth muscle

Indexed keywords

ACETYLCHOLINE; MONOCROTALINE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; POTASSIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTERY CONSTRICTION; ARTICLE; CARDIOVASCULAR FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; HEMODYNAMICS; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LUNG BLOOD VESSEL; MALE; NONHUMAN; NONHYPERCAPNIC ACIDOSIS; PRIORITY JOURNAL; PULMONARY ARTERIOLE REMODELING; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; RAT; RESPIRATORY ACIDOSIS; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

ACETYLCHOLINE; ACIDOSIS, RESPIRATORY; AIRWAY REMODELING; AMMONIUM CHLORIDE; ANIMALS; ANOXIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARBON DIOXIDE; CHOLINERGIC AGONISTS; HEART VENTRICLES; HYPERTENSION, PULMONARY; HYPERTROPHY; LUNG; MALE; MONOCROTALINE; NITROPRUSSIDE; ORGAN SIZE; PHENYLEPHRINE; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 84860531711     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00293.2011     Document Type: Article

References (80)

1. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121: 2747-2754, 2011.
2. Adnot S, Raffestin B, Eddahibi S, Braquet P, Chabrier PE. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest 87: 155-162, 1991.
3. Akhavein F, St-Michel EJ, Seifert E, Rohlicek CV. Decreased left ventricular function, myocarditis, and coronary arteriolar medial thickening following monocrotaline administration in adult rats. J Appl Physiol 103: 287-295, 2007.
4. Aoshima D, Murata T, Hori M, Ozaki H. Time-dependent phenotypic and contractile changes of pulmonary artery in chronic hypoxia-induced pulmonary hypertension. J Pharm Sci 110: 182-190, 2009.
5. Baber SR, Deng W, Master RG, Bunnell BA, Taylor BK, Murthy SN, Hyman AL, Kadowitz PJ. Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol 292: H1120-H1128, 2007.
6. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 137: 376-387, 2010.
7. Bauer NR, Moore TM, McMurtry IF. Rodent models of PAH: are we there yet? Am J Physiol Lung Cell Mol Physiol 293: L580-L582, 2007.
8. Brenninkmeijer L, Kuehl C, Miele Geldart A, Arons E, Christou H. Heme Oxygenase-1 does not mediate the effects of extracellular acidosis on vascular smooth muscle cell proliferation, migration, and susceptibility to apoptosis. J Vasc Res 48: 285-296, 2011.
9. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 109: 159-165, 2004.
10. Burger CD. Pulmonary hypertension in COPD: a review and consideration of the role of arterial vasodilators. COPD 6: 137-144, 2009.
11. Christou H, Bailey N, Kluger MS, Mitsialis SA, Kourembanas S. Extracellular acidosis induces heme oxygenase-1 expression in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 288: H2647-H2652, 2005.
12. Christou H, Morita T, Hsieh CM, Koike H, Arkonac B, Perrella MA, Kourembanas S. Prevention of hypoxia-induced pulmonary hypertension by enhancement of endogenous heme oxygenase-1 in the rat. Circ Res 86: 1224-1229, 2000.
13. Christou HA, Khalil RA. Sex hormones and vascular protection in pulmonary arterial hypertension. J Cardiovasc Pharmacol 56: 471-474, 2010.
14. Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, Stringer R, Jones P, Morrell NW, Jarai G, Walker C, Westwick J, Thomas M. A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 184: 1171-1182, 2011.
15. Connolly MJ, Aaronson PI. Key role of the RhoA/Rho kinase system in pulmonary hypertension. Pulm Pharmacol Ther 24: 1-14, 2011.
16. Cowan DB, Jones M, Garcia LM, Noria S, del Nido PJ, McGowan FX Jr. Hypoxia and stretch regulate intercellular communication in vascular smooth muscle cells through reactive oxygen species formation. Arterioscler Thromb Vasc Biol 23: 1754-1760, 2003.
17. Crossno JT Jr, Garat CV, Reusch JE, Morris KG, Dempsey EC, McMurtry IF, Stenmark KR, Klemm DJ. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol 292: L885-L897, 2007.
18. Daley E, Emson C, Guignabert C, de Waal Malefyt R, Louten J, Kurup VP, Hogaboam C, Taraseviciene-Stewart L, Voelkel NF, Rabinovitch M, Grunig E, Grunig G. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med 205: 361-372, 2008.
19. Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG, McMurtry IF. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 287: L656-L664, 2004.
20. Farber HW. The status of pulmonary arterial hypertension in 2008. Circulation 117: 2966-2968, 2008.
21. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 351: 1655-1665, 2004.
22. Fawcett J, Hsu FW, Tsao T, Rabkin R. Effect of metabolic acidosis on the insulin-like growth factor-I system and cathepsins B and L gene expression in the kidney. J Lab Clin Med 136: 468-475, 2000.
23. Fleming I, Busse R. NO: the primary EDRF. J Mol Cell Cardiol 31: 5-14, 1999.
24. Frid MG, Li M, Gnanasekharan M, Burke DL, Fragoso M, Strassheim D, Sylman JL, Stenmark KR. Sustained hypoxia leads to the emergence of cells with enhanced growth, migratory, and promitogenic potentials within the distal pulmonary artery wall. Am J Physiol Lung Cell Mol Physiol 297: L1059-L1072, 2009.
25. Fullerton DA, Hahn AR, McIntyre RC Jr. Mechanistic imbalance of pulmonary vasomotor control in progressive lung injury. Surgery 119: 98-103, 1996.
26. Geraci MW, Gao B, Shepherd DC, Moore MD, Westcott JY, Fagan KA, Alger LA, Tuder RM, Voelkel NF. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 103: 1509-1515, 1999.
27. Gillespie MN, Olson JW, Reinsel CN, O'Connor WN, Altiere RJ. Vascular hyperresponsiveness in perfused lungs from monocrotalinetreated rats. Am J Physiol Heart Circ Physiol 251: H109-H114, 1986.
28. Green ML, Hatch M, Freel RW. Ethylene glycol induces hyperoxaluria without metabolic acidosis in rats. Am J Physiol Renal Physiol 289: F536-F543, 2005.
29. Greenway S, van Suylen RJ, Du Marchie Sarvaas G, Kwan E, Ambartsumian N, Lukanidin E, Rabinovitch M. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am J Pathol 164: 253-262, 2004.
30. Guan J, Wu X, Arons E, Christou H. The p38 mitogen-activated protein kinase pathway is involved in the regulation of heme oxygenase-1 by acidic extracellular pH in aortic smooth muscle cells. J Cell Biochem 105: 1298-1306, 2008.
31. Guilluy C, Sauzeau V, Rolli-Derkinderen M, Guerin P, Sagan C, Pacaud P, Loirand G. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 146: 1010-1018, 2005.
32. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26: 858-863, 2005.
33. Homma N, Nagaoka T, Morio Y, Ota H, Gebb SA, Karoor V, McMurtry IF, Oka M. Endothelin-1 and serotonin are involved in activation of RhoA/Rho kinase signaling in the chronically hypoxic hypertensive rat pulmonary circulation. J Cardiovasc Pharmacol 50: 697-702, 2007.
34. Hoshikawa Y, Voelkel NF, Gesell TL, Moore MD, Morris KG, Alger LA, Narumiya S, Geraci MW. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med 164: 314-318, 2001.
35. Ignarro LJ. Nitric oxide. A novel signal transduction mechanism for transcellular communication. Hypertension 16: 477-483, 1990.
36. Ito T, Okada T, Miyashita H, Nomoto T, Nonaka-Sarukawa M, Uchibori R, Maeda Y, Urabe M, Mizukami H, Kume A, Takahashi M, Ikeda U, Shimada K, Ozawa K. Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats. Circ Res 101: 734-741, 2007.
37. Itoh H, Yokochi A, Yamauchi-Kohno R, Maruyama K. Effects of the endothelin ET(A) receptor antagonist, TA-0201, on pulmonary arteries isolated from hypoxic rats. Eur J Pharmacol 376: 233-238, 1999.
38. Ivy D, McMurtry IF, Yanagisawa M, Gariepy CE, Le Cras TD, Gebb SA, Morris KG, Wiseman RC, Abman SH. Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol 280: L1040-L1048, 2001.
39. Ivy DD, McMurtry IF, Colvin K, Imamura M, Oka M, Lee DS, Gebb S, Jones PL. Development of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptor-deficient rats: a new model of severe pulmonary arterial hypertension. Circulation 111: 2988-2996, 2005.
40. Ivy DD, Yanagisawa M, Gariepy CE, Gebb SA, Colvin KL, Mc-Murtry IF. Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. Am J Physiol Lung Cell Mol Physiol 282: L703-L712, 2002.
41. Jara A, Felsenfeld AJ, Bover J, Kleeman CR. Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease. Kidney Int 58: 1023-1032, 2000.
42. Kantores C, McNamara PJ, Teixeira L, Engelberts D, Murthy P, Kavanagh BP, Jankov RP. Therapeutic hypercapnia prevents chronic hypoxia-induced pulmonary hypertension in the newborn rat. Am J Physiol Lung Cell Mol Physiol 291: L912-L922, 2006.
43. Khalil RA, van Breemen C. Sustained contraction of vascular smooth muscle: calcium influx or C-kinase activation? J Pharmacol Exp Ther 244: 537-542, 1988.
44. Klings ES, Farber HW. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350: 2521-2522; author reply 2521-2522, 2004.
45. Lagna G, Ku MM, Nguyen PH, Neuman NA, Davis BN, Hata A. Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors. J Biol Chem 282: 37244-37255, 2007.
46. Laudi S, Trump S, Schmitz V, West J, McMurtry IF, Mutlak H, Christians U, Weimann J, Kaisers U, Steudel W. Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol Lung Cell Mol Physiol 293: L630-L638, 2007.
47. Lee JE, Hillier SC, Knoderer CA. Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease. J Intensive Care Med 23: 329-334, 2008.
48. Li X, Zhang X, Leathers R, Makino A, Huang C, Parsa P, Macias J, Yuan JX, Jamieson SW, Thistlethwaite PA. Notch3 signaling promotes the development of pulmonary arterial hypertension. Nat Med 15: 1289-1297, 2009.
49. Lucioni A, Womack C, Musch MW, Rocha FL, Bookstein C, Chang EB. Metabolic acidosis in rats increases intestinal NHE2 and NHE3 expression and function. Am J Physiol Gastrointest Liver Physiol 283: G51-G56, 2002.
50. Mam V, Tanbe AF, Vitali SH, Arons E, Christou HA, Khalil RA. Impaired vasoconstriction and nitric oxide-mediated relaxation in pulmonary arteries of hypoxia- and monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Exp Ther 332: 455-462, 2010.
51. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 55: 1915-1922, 2010.
52. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Puttagunta L, Michelakis ED. Gene therapy targeting surviving selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 115: 1479-1491, 2005.
53. Mitani Y, Ueda M, Komatsu R, Maruyama K, Nagai R, Matsumura M, Sakurai M. Vascular smooth muscle cell phenotypes in primary pulmonary hypertension. Eur Respir J 17: 316-320, 2001.
54. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Qiu D, Benson G, Pearl RG, Kao PN. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 108: 1640-1645, 2003.
55. Nowik M, Kampik NB, Mihailova M, Eladari D, Wagner CA. Induction of metabolic acidosis with ammonium chloride (NH4Cl) in mice and rats-species differences and technical considerations. Cell Physiol Biochem 26: 1059-1072, 2010.
56. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, McMurtry IF. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 100: 923-929, 2007.
57. Okada K, Tanaka Y, Bernstein M, Zhang W, Patterson GA, Botney MD. Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am J Pathol 151: 1019-1025, 1997.
58. Ooi H, Cadogan E, Sweeney M, Howell K, O'Regan RG, McLoughlin P. Chronic hypercapnia inhibits hypoxic pulmonary vascular remodeling. Am J Physiol Heart Circ Physiol 278: H331-H338, 2000.
59. Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, Ayres SM, Bergofsky EH, Brundage BH, Detre KM. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 80: 1198-1206, 1989.
60. + exchange and growth factors in pulmonary artery smooth muscle cell proliferation. Am J Respir Cell Mol Biol 14: 139-145, 1996.
61. Quinn DA, Du HK, Thompson BT, Hales CA. Amiloride analogs inhibit chronic hypoxic pulmonary hypertension. Am J Respir Crit Care Med 157: 1263-1268, 1998.
62. + exchange to pH regulation in pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 5: 586-591, 1991.
63. Rich S, Kaufmann E, Levy PS. The effect of high doses of calciumchannel blockers on survival in primary pulmonary hypertension. N Engl J Med 327: 76-81, 1992.
64. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821, 2005.
65. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, Ermert M, Weissmann N, Rose F, Guenther A, Walmrath D, Seeger W, Grimminger F. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 169: 39-45, 2004.
66. Shimoda LA, Sham JS, Sylvester JT. Altered pulmonary vasoreactivity in the chronically hypoxic lung. Physiol Res 49: 549-560, 2000.
67. + exchange in pulmonary artery smooth muscle from spontaneously hypertensive and Wistar-Kyoto rats. Am J Physiol Lung Cell Mol Physiol 269: L673-L680, 1995.
68. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111: 3105-3111, 2005.
69. Smith AM, Jones RD, Channer KS. The influence of sex hormones on pulmonary vascular reactivity: possible vasodilator therapies for the treatment of pulmonary hypertension. Curr Vasc Pharmacol 4: 9-15, 2006.
70. Spiekerkoetter E, Alvira CM, Kim YM, Bruneau A, Pricola KL, Wang L, Ambartsumian N, Rabinovitch M. Reactivation of gammaHV68 induces neointimal lesions in pulmonary arteries of S100A4/Mts1-overexpressing mice in association with degradation of elastin. Am J Physiol Lung Cell Mol Physiol 294: L276-L289, 2008.
71. Stehlik J, Movsesian MA. Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure. J Card Fail 15: 31-34, 2009.
72. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 104: 236-244, 2009.
73. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297: L1013-L1032, 2009.
74. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15: 427-438, 2001.
75. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, Scerbavicius R, Burns N, Cool C, Wood K, Parr JE, Boackle SA, Voelkel NF. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med 175: 1280-1289, 2007.
76. Vitali SH, Mitsialis SA, Liang OD, Liu X, Fernandez-Gonzalez A, Christou H, Wu X, McGowan FX, Kourembanas S. Divergent cardiopulmonary actions of heme oxygenase enzymatic products in chronic hypoxia. PLoS One 4: e5978, 2009.
77. Wang XX, Zhang FR, Shang YP, Zhu JH, Xie XD, Tao QM, Chen JZ. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 49: 1566-1571, 2007.
78. White RJ, Meoli DF, Swarthout RF, Kallop DY, Galaria II, Harvey JL, Miller CM, Blaxall BC, Hall CM, Pierce RA, Cool CD, Taubman MB. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 293: L583-L590, 2007.
79. Xu EZ, Kantores C, Ivanovska J, Engelberts D, Kavanagh BP, McNamara PJ, Jankov RP. Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension. Am J Physiol Heart Circ Physiol 299: H1854-H1864, 2010.
80. Yin N, Kaestle S, Yin J, Hentschel T, Pries AR, Kuppe H, Kuebler WM. Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease. Crit Care Med 37: 980-986, 2009.